Agenus (AGEN) Retained Earnings (2010 - 2026)
Agenus (AGEN) posted quarterly Retained Earnings of -$2.1 billion for Q1 2026, up 2.57% year-over-year from -$2.1 billion in Q1 2025, and down 212.13% quarter-over-quarter from $1.9 billion in Q4 2025.
Analysis
Agenus (AGEN) Retained Earnings (2010 - 2026) Analysis & Trends
Agenus' Retained Earnings history runs 17 years deep, the most recent figure standing at -$2.1 billion for Q1 2026.
- In Q1 2026, Retained Earnings rose 2.57% year-over-year to -$2.1 billion; the TTM figure through Mar 2026 stood at -$2.1 billion (up 2.57% YoY), while the FY2025 annual figure was $1.9 billion, up 136848.21% from the prior year.
- Retained Earnings for Q1 2026 stood at -$2.1 billion, down from $1.9 billion in the prior quarter.
- The five-year high for Retained Earnings was $1.9 billion in Q4 2025, with the low at -$2.2 billion in Q1 2025.
- The 5-year median for Retained Earnings is -$1.5 billion (2022), against an average of -$579.6 million.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings plunged 149600.6% in 2022, then soared 275906.21% in 2023.
- Agenus' Retained Earnings stood at -$1.7 billion in 2022, then fell by 14.37% to -$2.0 billion in 2023, then jumped by 99.93% to -$1.4 million in 2024, then surged by 136848.21% to $1.9 billion in 2025, then sank by 212.13% to -$2.1 billion in 2026.
- Business Quant data shows AGEN's Retained Earnings at -$2.1 billion in Q1 2026, $1.9 billion in Q4 2025, and $1.9 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Agenus | 340.21 Mn | 340.21 Mn | 34.52 Mn | -2.14 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.14 Bn |
| Mar 31, 2026 | -2.14 Bn |
| Dec 31, 2025 | -2.18 Bn |
| Sep 30, 2025 | -2.20 Bn |
| Jun 30, 2025 | -2.24 Bn |
| Mar 31, 2025 | -2.21 Bn |
| Dec 31, 2024 | -2.18 Bn |
| Sep 30, 2024 | -2.14 Bn |
| Jun 30, 2024 | -2.10 Bn |
| Mar 31, 2024 | -2.02 Bn |
| Dec 31, 2023 | -1.96 Bn |
| Sep 30, 2023 | -1.91 Bn |
| Jun 30, 2023 | -1.85 Bn |
| Mar 31, 2023 | -1.80 Bn |
| Dec 31, 2022 | -1.71 Bn |
| Sep 30, 2022 | -1.64 Bn |
| Jun 30, 2022 | -1.60 Bn |
| Mar 31, 2022 | 1.55 Bn |
| Dec 31, 2021 | 1.52 Bn |
| Sep 30, 2021 | 1.46 Bn |